Skip to main content
. 2016 Nov 30;30(18):2845–2853. doi: 10.1097/QAD.0000000000001252

Table 2.

Tuberculosis treatment outcome in the 2013 treatment cohort of reported tuberculosis cases with tuberculosis disease sensitive to isoniazid or rifampicin in 16 European Union and European Economic Area countries reporting on HIV status.

Tuberculosis treatment outcome HIV-positive TB cases, N (%) HIV-negative TB cases, N (%) TB cases with unknown HIV status, N (%) Total number of TB cases, N (%)
Total 968 (100.0) 19 232 (100.0) 11 154 (100.0) 31 354 (100.0)
Success 560 (57.9)a 16 068 (83.5)a 8403 (75.9) 25 031 (79.9)
Died 133 (13.7)a 1080 (5.6)a 1077 (9.0) 2290 (7.3)
Failed 19 (2.0) 298 (1.5) 191 (2.0) 508 (1.6)
Lost to follow-up 75 (7.7)a 876 (4.6) 639 (5.4) 1590 (5.1)
Still on treatment 67 (6.9)a 299 (1.6)a 178 (1.0) 544 (1.7)
Not evaluated 114 (11.8)a 611 (3.2)a 666 (6.7) 1391 (4.4)

TB, tuberculosis. Member states: Belgium, Bulgaria, Czech Republic, Estonia, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, Norway, Portugal, Romania, Slovakia, Slovenia and Spain.

aSignificantly different between HIV-positive and HIV-negative patients, P value <0.001.

HHS Vulnerability Disclosure